SEQUANA MEDICAL ANNOUNCES DECISION OF MAJOR SHAREHOLDERS TO INVEST IN SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium, 6 December 2024 – (Euronext Brussels: SEQUA) (the "Company" or "Sequana ...
Comprehensive Insights Provided into the Epidemiology Segments and Forecasts, the Future Growth Potential of Diagnosis Rate, Disease Progression, and Diagnostic GuidelinesDublin, Dec. 05, 2024 (GLOBE ...
AstraZeneca's IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the presentation of the Phase 3 ...
Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo AstraZeneca's IMFINZI (durvalumab) has been approved in the US for the treatment of adult ...